A Turning Point for Narcotics Regulation in Indian Pharma
For decades, India’s pharmaceutical manufacturers have operated under an NDPS compliance regime where a documentation lapse could be treated with the same severity as deliberate diversion. That is now officially changing. At iPHEX 2026 — the flagship pharma exhibition organised by Pharmexcil in New Delhi on September 9, 2026 — senior regulators confirmed that the Narcotic Drugs and Psychotropic Substances (NDPS) Act is undergoing a formal process of amendment, with “proportionality” as a central theme of the deliberations. This is arguably the most significant signal yet that India’s controlled substances framework is heading toward a risk-based, rather than purely punitive, model.
What Was Said, and by Whom
Speaking at a session on rationalising criminal provisions governing business compliance, Dr Ranga Chandrashekhar, Joint Drug Controller at CDSCO, said the organisation has examined the drug approval pathway to identify areas where regulatory intervention can be reduced without compromising quality, pointing to measures where certain requirements have moved from prior approval to prior intimation.
More directly relevant to narcotics compliance, Brijendra Chowdhary, Deputy Narcotics Commissioner at the Central Bureau of Narcotics, said regulation should facilitate legitimate pharmaceutical activity while maintaining strong safeguards against diversion, stressing that the challenge is to enable legitimate economic expansion of the pharmaceutical industry while preventing illicit diversion, and that there should be proportionality, a clear distinction between a legitimate error and malfeasance, risk-based enforcement, and zero tolerance against drug trafficking and diversion. Crucially, he added that the Central Bureau of Narcotics is working towards an ecosystem of self-regulation and voluntary compliance, supported by greater engagement and awareness among industry, and confirmed the NDPS Act is undergoing a process of amendment with proportionality forming part of the deliberations.
Industry pushed back on one point worth noting: proportionality should not mean vague rules. Meera Vanjari, Chief General Counsel at Cipla Ltd., stressed that greater proportionality also requires clearer and more consistently interpreted regulations, stating that the industry does not want diluted regulations but wants them to be more specific, objective, easy to interpret and not open to subjectivity. This is a critical caveat for compliance teams: reform is coming, but it will likely raise the bar on documentation clarity even as it eases blanket punitive treatment.
The policy direction was echoed at the government-wide level too. Dr Sonali Rawal of NITI Aayog said the government’s approach is not to do away with necessary regulation, but to simplify processes where delays can be avoided, describing the underlying basis of this process as “Jan Vishwas” — trust in industry partners and regulators to undertake processes in parallel or simplify unnecessary requirements.
The Bigger Enforcement Backdrop: Vision Document 2026-2029
The proportionality push at iPHEX does not exist in isolation — it is unfolding against a backdrop of intensified enforcement architecture. On June 26, 2026, Union Home Minister Amit Shah chaired the 10th Apex-Level Meeting of the Narco-Coordination Centre (NCORD) and released the Vision Document on Drug Control (2026-2029), a three-year national strategy built on the mantra “Detect, Disrupt, and Destroy” for action against narcotics networks from source to kingpin.
For pharmaceutical manufacturers specifically, the document’s Precursor and Synthetic Drug Control pillar is the most relevant. The Vision Document focuses on dismantling cartels, securing borders, controlling precursors via the PREP portal, expanding Nasha Mukt Bharat Abhiyaan, and enhancing capacity building. Separately, and just days before the NCORD meeting, the NCB launched a Voluntary Code of Conduct for the chemical industry in Ahmedabad on June 17, 2026, urging firms to tighten monitoring and report suspicious precursor transactions.
The scale of enforcement activity underlying this shift is stark. The NCB Annual Report 2025, released alongside the Vision Document, recorded an all-time high of over 1.48 lakh cases and seizures of more than 1,200 tonnes of narcotics and psychotropic substances, ranging from plant-based drugs to synthetic substances, diverted pharmaceuticals and precursor chemicals. This confirms that diverted pharmaceutical products remain a recognised category within India’s broader narcotics seizure data — not a marginal concern.
Financial Investigation Now Mandatory in Major Cases
One operational change pharma compliance and legal teams must note: the Home Minister directed that financial investigations under the Enforcement Directorate (ED) and the Prevention of Money Laundering Act (PMLA) should be made mandatory in all major drug cases, to break the financial backbone of drug cartels. Any pharmaceutical company caught in an NDPS enforcement action — even one arising from a supply-chain lapse — should now anticipate parallel financial scrutiny, not just a Drugs Controller or CBN inquiry. Additionally, work is underway to establish special NDPS courts for speedy disposal of cases and to improve conviction rates, meaning cases will likely move faster through the legal system than in previous years.
What This Means for Pharmaceutical Companies: Practical Takeaways
1. Get Ahead of the Voluntary Compliance Framework
With CBN explicitly building an ecosystem of self-regulation, companies handling precursor chemicals, essential narcotic drugs, or psychotropic substances should not wait for the amended Act to be notified. Manufacturers and API producers should proactively adopt internal suspicious-transaction flagging protocols aligned with the NCB’s Voluntary Code of Conduct, treating early adoption as a compliance asset rather than an optional gesture.
2. Tighten Documentation Now — Proportionality Cuts Both Ways
Since industry itself has asked for clearer, more objective rules rather than looser ones, companies should expect the amended NDPS Act to sharpen — not soften — documentation standards even as it introduces graded penalties. Distributor agreements, batch-level tracking records, CBN registration papers, and import/export authorisations should all be audited now for consistency and completeness.
3. Prepare for Parallel Financial Scrutiny
Given the mandatory ED/PMLA linkage in major cases, companies should ensure their finance and legal teams have a coordinated response protocol for any NDPS-related enforcement action, since a documentation issue could now trigger scrutiny well beyond the Drugs Controller’s office.
4. Track the Amendment Process Closely
The amendment to the NDPS Act is still in deliberation — no final text or notification date has been announced yet. Companies should monitor Department of Revenue and CBN communications closely over the coming months, as the shift from “prior approval” to “prior intimation” models already seen in NDCT Rules amendments may be extended to certain narcotics-related procedures.
5. Engage With the Precursor Control Push
Any company using precursor chemicals in API manufacturing should review its exposure under the PREP portal framework and ensure procurement, storage, and transfer records for regulated chemicals are audit-ready, given the heightened border and cartel-disruption focus under the Vision Document 2026-2029.
The Road Ahead
India’s narcotics compliance regime for pharma is entering a genuinely dual-track phase: enforcement infrastructure is scaling up sharply — new NCB zonal offices, mandatory financial investigations, special courts, record seizure volumes — while, simultaneously, the government is signalling a more calibrated, risk-based approach to procedural compliance for legitimate industry players. Companies that treat this as a green light to relax are misreading the signal; companies that use this window to strengthen documentation, adopt voluntary compliance codes, and build audit-ready records will be best positioned once the amended Act takes final shape.
ACPL’s regulatory experts can help you navigate NDPS Act compliance. Contact us at info@acplgroupindia.co.in or call +91-9266665201 for a consultation.